Grifols SA (GRFS) Stock AnalysisGRFSGrifols SA

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use. It operates in the Healthcare sector.

Grifols SA (GRFS) is currently at a price of 7.46, with a forward P/E of 5.81, suggesting it may be undervalued. However, the stock has a significant risk with hedge funds increasing their selling activity by 986.97% over the last quarter, indicating a lack of confidence in the stock's near-term performance. While the recent profit growth of 28.7% in H1 2026 is promising, the operational challenges highlighted by Health Canada's restrictions on plasma centers pose a serious risk to its reputation and future earnings.

4 analysts cover GRFS: 3 rate it Buy, 0 Hold and 1 Sell.